Antisense Therapeutics Limited Stock Earnings Per Share
Antisense Therapeutics Limited fundamentals help investors to digest information that contributes to Antisense Therapeutics' financial success or failures. It also enables traders to predict the movement of Antisense Pink Sheet. The fundamental analysis module provides a way to measure Antisense Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Antisense Therapeutics pink sheet.
Antisense |
Antisense Therapeutics Limited Company Earnings Per Share Analysis
Antisense Therapeutics' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Antisense Therapeutics Earnings Per Share | (0.01) X |
Most of Antisense Therapeutics' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Antisense Therapeutics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
CompetitionAccording to the company disclosure, Antisense Therapeutics Limited has an Earnings Per Share of -0.011 times. This is 100.13% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The earnings per share for all United States stocks is 100.35% higher than that of the company.
Antisense Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Antisense Therapeutics' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Antisense Therapeutics could also be used in its relative valuation, which is a method of valuing Antisense Therapeutics by comparing valuation metrics of similar companies.Antisense Therapeutics is currently under evaluation in earnings per share category among its peers.
Antisense Fundamentals
Return On Equity | -0.43 | |||
Return On Asset | -0.25 | |||
Operating Margin | (3.28) % | |||
Current Valuation | 27.82 M | |||
Shares Outstanding | 669.04 M | |||
Shares Owned By Insiders | 19.30 % | |||
Shares Owned By Institutions | 4.93 % | |||
Price To Earning | (3.62) X | |||
Price To Book | 3.05 X | |||
Price To Sales | 24.46 X | |||
Revenue | 1.78 M | |||
Gross Profit | 1.71 M | |||
EBITDA | (7.52 M) | |||
Net Income | (5.81 M) | |||
Cash And Equivalents | 19.23 M | |||
Cash Per Share | 0.03 X | |||
Total Debt | 227.4 K | |||
Debt To Equity | 0.01 % | |||
Current Ratio | 19.14 X | |||
Book Value Per Share | 0.03 X | |||
Cash Flow From Operations | (7.81 M) | |||
Earnings Per Share | (0.01) X | |||
Number Of Employees | 12 | |||
Beta | 0.67 | |||
Market Capitalization | 41.78 M | |||
Total Asset | 22.44 M | |||
Retained Earnings | (53 M) | |||
Working Capital | 4 M | |||
Current Asset | 5 M | |||
Current Liabilities | 1000 K | |||
Net Asset | 22.44 M |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Antisense Pink Sheet
If you are still planning to invest in Antisense Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Antisense Therapeutics' history and understand the potential risks before investing.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |